No four consecutive quarters could be summed for EPS (Diluted); these figures use the latest fiscal year, not a trailing twelve months.
Some figures named '(TTM)' on this payload are the latest FISCAL YEAR, not a trailing twelve months — eps_ttm (fiscal year ended 2025-12-31). No four consecutive quarters could be summed for them — for an IFRS 20-F filer that is every income-statement line (no quarterly income statement is tagged to EDGAR at all); for a US filer it is usually one line the quarterly tagging skips. Each field's own basis is on field_basis.
full derived coverage requires a plan
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
— Months · distinct values (the real sample size).
Metric
Today
Own median
Own range
%ile
z
Sector med.
mo · distinct
20.95×
26.05×
27th
−0.35σ
24.86×
139 · 139
36.9%
27.6%
69th
+0.91σ
−36.9%
127 · 11
ROIC (FY)
—
no reconstructed observations for this name and metric.
28.1%
17.0%
97th
+1.14σ
−21.3%
115 · 10
60.3%
9.8%
100th
+2.79σ
5.1%
141 · 139
8.4%
14.1%
27th
+0.05σ
8.4%
103 · 9
3.1%
4.8%
35th
−0.65σ
9.0%
79 · 7
Market Cap
$376.37B
not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series.
Own median 26.05× × $7.28 = $189.63vs the $152.55 close · earnings held constant
Own multiple
P/E
Implied price
vs close
10th percentile
13.34×
$97.12
−36.3%
25th percentile
17.52×
$127.52
−16.4%
median
26.05×
$189.63
+24.3%
75th percentile
38.13×
$277.56
+82.0%
90th percentile
82.07×
$597.45
+291.6%
today
20.95×
$152.55
—
Reference computation · 139 monthly P/E observations in Full · EPS basis FY2025 EPS (Diluted) $7.28 · close $152.55 (2026-08-21)ⓘ
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Percentile through time (point-in-time cohort)
Loading the monthly cohort placement…
▸Comp setname your own peers — pick a pool or add tickers
Covered pool$978.69B +7.6%/yr 2020→2025Concentration484 of 10,000fragmented · top 3 hold 22.9% · −25 pts since 2020MRK6.6% · rank 3 of 349 · +0.5pp over 5y· CV 0.07 · σ 0.6pp
Who holds the poolCY2025 · bars scaled to the largest member
Growth, restated as sharewhere each pace has to END UP, by 2030
Its own realised pace6.6% → 5.4%
The pace the price requires— The growth today's price requires (our reverse-DCF) is a Pro metric — the realized-pace runway above is free.
MRK share over timelast 6 of 10 published years
Calendar year
2020
2021
2022
2023
2024
2025
Share of covered pool
5.8%
5.7%
6.6%
6.9%
6.8%
6.6%
coverage: 322 of the 385 members that…
Share of covered industry revenue · n=349 in Pharmaceuticals & Biotechnology · CY2025 pool · built 2026-08-22 not market shareⓘ
Covered filers only, not market share — private and uncovered companies are missing, so every share here reads high. Years are FX-converted and published only once most of the pool has filed.
